Ultra-long acting β2 agonists (uLABA) are relatively new anti-asthma medications of which there are three different formulations currently available: olodaterol, indacaterol and vilanterol. The first two formulations have been shown to exert bronchoprotective effects; they are able to prevent airway smooth muscle contraction upon exposure to constricting stimuli. However, studies have found that these two drugs produce different degrees and durations of bronchoprotection against methacholine.
https://ift.tt/2ufEgGc
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου